Makiko Hatori Email & Phone Number

Developing clinical diagnostic assays utilizing single-cell whole genome sequencing to enhance the accuracy of genetic profiling.Implementing Illumina and Nanopore sequencing to streamline data collection processes, reducing turnaround times and increasing throughput.

• 【Development of NGS based early stage cancer diagnostic kits for nanopore sequencer】
• Point lead for designing and evaluating sequencing adapters. Successfully increased the NGS library preparation efficiency by 20% compared to original adapter design.
• Proposed novel ideas to improve assay performance that involved increasing assay sensitivity. As a result assay efficiency was increased by 8% compared to existing assay. The ideas also lead to a significant reduction.
• Organized meetingWorked closely with manufacturing and late development teams to transfer project to next phase

San Francisco Bay Area

• 【Established novel droplet generation methods for single cell assays which does not require specialized skills】
• First author for 2 papers and in charge of experiment planning, experiment execution, and manuscript preparation.
• Significantly increases the accessibility of droplet assays for laboratories that do not specialize in microfluidics. By using vortexing as a means of droplet formation, the method eliminates complex, expensive.
• This scalable droplet generation method enables the preparation of up to 40 millions samples with reduced preparation time from 12 hours to 30 seconds.
• Successfully developed 3 applications with this method, involving ddPCR, single cell RNA sequencing and DNA sequencing
• Filed for 3 patents【Development of point of care test kit for COVID】

United States

• 【Revealed the mechanism of signaling protein dispersion during tumorigenesis】
• To understand signaling pathway, tagged endogenous signaling protein using Crispr-Cas9
• Designed and cloned template and gRNA vector for tag and indel introduction
• Fluorescent live imaging of tagged proteins reveal the mechanism of signaling protein dispersion during tumorigenesis

Tokyo, Japan

• 【Conducted clinical trial】
• Worked as clinical research associate
• Design the protocol for atrial fibrillation for phase II and asthma for phase I

Japan

• 【Discovered a new protein that has crucial role for membrane trafficking events】
• To understand tumor genesis and virus infection, I studied molecular mechanisms for clathrin-mediated endocytosis using budding yeast.
• Generated over 100 of mutant strains (knockout/knockin/point mutation/indels).
• Discovered the a new protein, Srv2p, required for this pathway and demonstrated in vivo role of this protein in the regulation of the actin cytoskeleton.